DUBLIN–(BUSINESS WIRE)–The “DNA Gyrase Inhibitors – Pipeline Insight, 2022” drug pipelines have been added to from ResearchAndMarkets.com offer.
This “DNA Gyrase Inhibitors – Pipeline Insight, 2022” report provides comprehensive insights on 12+ companies and 13+ drugs under development in the DNA Gyrase Inhibitors pipeline landscape.
It covers pipeline drug profiles, including clinical and non-clinical stage products. It also covers therapeutic evaluation by product type, stage, route of administration and molecule type. It also highlights inactive pipeline products in that space.
Report Highlights
Companies and academics are working to assess challenges and seek out opportunities that can influence DNA gyrase inhibitor R&D. Therapies under development focus on new approaches for DNA gyrase inhibitors.
DNA Gyrase Inhibitors Emerging Drug Chapters
This segment of the DNA Gyrase Inhibitors report contains its detailed analysis of various drugs at different stages of clinical development including Phase III, II, I, Preclinical and Discovery. It also helps to understand details of clinical trials, expressive pharmacological action, agreements and collaborations, as well as the latest news and press releases.
DNA Gyrase Inhibitors Emerging Drugs
TNP 2092: TenNor Therapeutics
TNP 2092 (CBR-2092) is a hybrid non-cleavable rifampin-quinolone antimicrobial agent composed of covalently conjugated pharmacophores rifamycin SV and 4H-4-oxo-quinolizine. The drug is in Phase II clinical studies for the treatment of bacterial infections and skin and soft tissue infections. In January 2020, TNP 2092 received orphan drug designation from the US FDA to treat prosthetic joint infections. TenNor has already received FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for TNP-2092.
Zoliflodacin: Entasis Therapeutics
Zoliflodacin (ETX0914) is an orally bioavailable antibacterial agent. It is a novel bacterial spiropyrimidinetrione DNA gyrase inhibitor. The drug is in Phase III clinical development studies for the treatment of gonorrhea.
Key Players Working on DNA Gyrase Inhibitors
Approx. 12+ key companies developing DNA gyrase inhibitors. Among the companies whose DNA gyrase inhibitor drug candidates are at the most advanced stage, ie in phase III, are Entasis Therapeutics.
Key players
-
Therapeutic Entasis
-
MerLion Pharmaceuticals
-
TenNor Therapy
-
Spero Therapeutic
-
NeuroSense Therapeutics
-
PolyActiva
-
Therapeutic Ocumension
-
Microbiotix
Key products
-
Zoliflodacin
-
Finafloxacin
-
NPT 2092
-
SPR 720
-
Celecoxib/ciprofloxacin
-
Preventive endophthalmitis implant
-
Moxifloxacin/dexamethasone
-
SPR-719
Research program
Main topics covered:
introduction
Summary
DNA Gyrase Inhibitors: Overview
-
Structure
-
Action mechanism
Pipeline therapeutics
Therapeutic assessment
-
Assessment by product type
-
Assessment by stage and type of product
-
Evaluation by route of administration
-
Assessment by stage and route of administration
-
Evaluation by type of molecule
-
Evaluation by stage and type of molecule
DNA Gyrase Inhibitors – Analytical Perspective
Late-stage products (Phase III)
Zoliflodacin: Entasis Therapeutics
-
Product Description
-
Research and development
-
Product development activities
Mid-term products (Phase II)
TNP 2092: TenNor Therapeutics
-
Product Description
-
Research and development
-
Product development activities
Early Stage Products (Phase I)
Preventive endophthalmitis implant: PolyActiva
-
Product Description
-
Research and development
-
Product development activities
Products in the preclinical and discovery phase
SPR-719: Spero Therapeutic
-
Product Description
-
Research and development
-
Product development activities
Inactive products
DNA Gyrase Inhibitors Key Companies
DNA Gyrase Inhibitors Key Products
DNA Gyrase Inhibitors – Unmet Needs
DNA Gyrase Inhibitors – Market Drivers and Barriers
DNA Gyrase Inhibitors – Future Perspectives and Conclusion
DNA Gyrase Inhibitors Opinion of the Analysts
DNA Gyrase Inhibitors Key Companies
appendix
For more information on this Drug Pipelines report, visit https://www.researchandmarkets.com/r/u8lxf9
